Status:
ACTIVE_NOT_RECRUITING
Potassium Supplementation in CKD
Lead Sponsor:
Erasmus Medical Center
Collaborating Sponsors:
Dutch Kidney Foundation
University Medical Center Groningen
Conditions:
Renal Insufficiency, Chronic
Potassium Depletion
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The current high-sodium, low-potassium diet contributes to the high prevalence of high blood pressure (hypertension). Indeed, the anti-hypertensive effects of potassium supplementation are well-establ...
Eligibility Criteria
Inclusion
- CKD 3b or 4 (45 - 15 ml/min/1.73 m2)
- Δ eGFR (as estimated by the CKD-EPI equation) \> 2 ml/min/1.73 m2/year (in preceding ≥ 1 year with at least 3 measurements)
- Hypertension (defined as office blood pressure \> 140/90 mmHg or use of anti-hypertensive medication)
Exclusion
- Hyperkalemia (serum potassium \> 5.5 mmol/l) at study visit V0
- Medical reasons to continue dual RAAS-blockade, mineralocorticoid receptor blockers, potassium-sparing diuretics, or oral potassium binders.
- Patients with previous history of ventricular cardiac arrhythmia
- Patients with a life expectancy \< 6 months
- Expected initiation of renal replacement therapy \< 2 years
- Incapacitated subjects
- Women who are pregnant, breastfeeding or consider pregnancy in the coming 2 years.
Key Trial Info
Start Date :
July 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
532 Patients enrolled
Trial Details
Trial ID
NCT03253172
Start Date
July 1 2017
End Date
October 1 2026
Last Update
December 27 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Academic Medical Center Amsterdam
Amsterdam, Netherlands
2
University Medical Center Groningen
Groningen, Netherlands
3
Leiden University Medical Center
Leiden, Netherlands
4
Erasmus MC
Rotterdam, Netherlands